CINCINNATI, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based...
Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company...
– Next-generation sequencing platform will provide up to three times more data output per hour than other benchtop instruments, while...
~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one...
MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on...
Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with...
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of...
Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust...
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...
CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an...
1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and RejectionSOUTH SAN FRANCISCO, Calif.,...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives...
atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet...
CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of...
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101...
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response...
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Data from third patient cohort confirm...
GATINEAU, Quebec, Dec. 16, 2021 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced...
2022 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Silent period11 January 2022Annual report 20218...
Correction – Admission Date for New Ordinary Shares Included This announcement contains inside information for the purposes of Article 7...
